Amy Abernethy

By Peter Page. The agency is worried legitimizing over-the-counter CBD will mean the end of Big Pharma interest in developing new drugs. A top FDA official who recently briefed the Senate Agriculture Committee on the status of the agency’s effort to regulate CBD. It’s not going...